Organisation paid for research Program year 2025 Source: CMS Open Payments

Cincyscience

Neither a doctor nor a teaching hospital

Research payments

$2,044,683

273 payments

Through program year 2025, Cincyscience is reported as receiving $2,044,683 in research payments, across 273 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $196,549 51
2024 Research $312,130 48
2023 Research $273,455 51
2022 Research $371,618 40
2021 Research $204,902 42
2020 Research $535,258 31
2019 Research $150,771 10

Breakdown

Who paid Research payments · program years 2019–2025
  1. Allergan Inc. $965,650 86 payments
  2. AbbVie, Inc. $737,464 90 payments
  3. Alkermes, Inc. $225,713 85 payments
  4. Janssen Research & Development, LLC $115,856 12 payments
Studies the money was for Research payments · program years 2019–2025
  1. Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder $272,738 23 payments
  2. Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri $266,557 10 payments
  3. A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $218,075 10 payments
  4. Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder $213,498 19 payments
  5. A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) $145,120 61 payments
  6. A Short term Exploratory Study to Evaluate Safety Tolerability and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have an Inadequate Response to an SSRI and Psychotherapy $115,856 12 payments
  7. Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri $99,021 22 payments
  8. A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder $84,557 14 payments
  9. A Double Blind, Placebo- and Active Controlled Evaluation of the Safety and Efficacy of Levomilnacipran Er in Adolescent Patients With Major Depressive Disorder $77,337 4 payments
  10. A 6-week, Multicenter, Randomized, Double-blind, Parallel-group,Placebo-controlled Study of the Efficacy and Safety of Cariprazine in Pediatric Participants (10 to 17 years of age) in the Treatment of Depressive Episodes Associated with Bipolar I Disorder $71,874 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record